Fetuin‐A, inter‐α‐trypsin inhibitor, glutamic acid and ChoE (18:0) are key biomarkers in a panel distinguishing mild from critical coronavirus disease 2019 outcomes
Open Access
- 24 January 2022
- journal article
- research article
- Published by Wiley in Clinical and Translational Medicine
- Vol. 12 (1) , e704
Abstract
No abstract availableKeywords
Funding Information
- Institut d'Investigació Sanitària Pere Virgili
This publication has 8 references indexed in Scilit:
- Discovery Proteomics for COVID-19: Where We Are NowJournal of Proteome Research, 2021
- Multiomics: unraveling the panoramic landscapes of SARS-CoV-2 infectionCellular & Molecular Immunology, 2021
- Diagnosis and Treatment Protocol for COVID-19 Patients (Tentative 8th Edition)Infectious Diseases & Immunity, 2021
- SARS-CoV-2 and Glutamine: SARS-CoV-2 Triggered Pathogenesis via Metabolic Reprograming of Glutamine in Host CellsFrontiers in Molecular Biosciences, 2021
- The four horsemen of a viral Apocalypse: The pathogenesis of SARS-CoV-2 infection (COVID-19)EBioMedicine, 2020
- The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19?Cell Host & Microbe, 2020
- Plasma metabolomic and lipidomic alterations associated with COVID-19National Science Review, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020